Financials data is unavailable for this security.
View more
Year on year Sumitomo Pharma Co Ltd 's revenues fell -43.38% from 555.54bn to 314.56bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 74.51bn to a larger loss of 314.97bn.
| Gross margin | 59.56% |
|---|---|
| Net profit margin | -81.54% |
| Operating margin | -80.70% |
| Return on assets | -28.68% |
|---|---|
| Return on equity | -106.22% |
| Return on investment | -51.21% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Sumitomo Pharma Co Ltd fell by 114.43bn. Cash Flow from Financing totalled 77.85bn or 24.75% of revenues. In addition the company used 240.76bn for operations while cash from investing totalled 33.04bn.
| Cash flow per share | -620.77 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 287.37 |
|---|---|
| Tangible book value per share | -640.26 |
More ▼
Balance sheet in JPYView more
| Current ratio | 0.6412 |
|---|---|
| Quick ratio | 0.424 |
| Total debt/total equity | 3.41 |
|---|---|
| Total debt/total capital | 0.7732 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -322.71%, respectively.
| Div yield(5 year avg) | 1.83% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -107.05 |
More ▼
